# EDGAR Filing Document

**Accession Number:** 0001733257
**File Stem:** 0000950170-23-001236
**Filing Date:** 2023-1
**Character Count:** 5577
**Document Hash:** 9876dbc8471c333455c62b43783d5509
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-001236.hdr.sgml**: 20230126

**ACCESSION NUMBER**: 0000950170-23-001236

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230125

**ITEM INFORMATION**: Termination of a Material Definitive Agreement

**FILED AS OF DATE**: 20230126

**DATE AS OF CHANGE**: 20230126

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Finch Therapeutics Group, Inc.
- **CENTRAL INDEX KEY:** 0001733257
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 823433558
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40227
- **FILM NUMBER:** 23558141

**BUSINESS ADDRESS:**
- **STREET 1:** 200 INNER BELT ROAD
- **CITY:** SOMERVILLE
- **STATE:** MA
- **ZIP:** 02143
- **BUSINESS PHONE:** 617-229-6499

**MAIL ADDRESS:**
- **STREET 1:** 200 INNER BELT ROAD
- **CITY:** SOMERVILLE
- **STATE:** MA
- **ZIP:** 02143

?xml version="1.0" encoding="ASCII"? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

**FORM** 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** January 25, 2023<br>

------

Finch Therapeutics Group, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-40227 | 82-3433558 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 200 Inner Belt Road |  |  |
| Somerville**,** Massachusetts |  | 02143 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (617) 229-6499<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | |
|:---|:---|
| **<br>Title of each class** | **<br>Name of each exchange on which registered** |
| Common Stock $0.001 par value per share<br> FNCH | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 1.02 Termination of a Material Definitive Agreement.**

On January 25, 2023, Finch Therapeutics Group, Inc. (the "Company") provided notice of its intention to voluntarily prepay all outstanding principal, accrued and unpaid interest, fees, costs and expenses, equal to $16.2 million in the aggregate (the "Payoff Amount"), under the Loan and Security Agreement (the "Loan Agreement"), dated as of May 11, 2022, by and among the Company and each of its subsidiaries, the several banks and other financial institutions or entities from time to time parties to the Loan Agreement (collectively, the "Lenders"), and Hercules Capital, Inc., in its capacity as administrative agent and collateral agent for itself and the Lenders. The Payoff Amount includes a prepayment charge of $330,000, equal to 2.2% of the outstanding principal, and an end of term fee of $825,000. Upon receipt by the Lender of the Payoff Amount on January 25, 2023, all obligations, covenants, debts and liabilities of the Company under the Loan Agreement were satisfied and discharged in full, and the Loan Agreement and all other documents entered into in connection with the Loan Agreement were terminated.

The Loan Agreement provided for a term loan with aggregate maximum borrowings of up to $55.0 million (the "Term Loan"). Under the Loan Agreement, the Company borrowed $15.0 million. The Term Loan bore interest at a variable annual rate equal to the greater of (i)(a) 4.05% plus (b) the Prime Rate (as reported in the Wall Street Journal) and (ii) 7.55%. Interest-only payments on the borrowings under the Loan Agreement were due through December 1, 2024. After the interest-only payment period, borrowings under the Loan Agreement were due in equal monthly payments of principal and accrued interest until November 1, 2026.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **FINCH THERAPEUTICS GROUP, INC.** |
| Date: | January 26, 2023 | By:  | /s/ Mark Smith |
|  |  |  | Mark Smith, Ph.D.<br>Chief Executive Officer |

---

------